

United States Department of Agriculture
Special Provisions
Grants and Assistance Type Cooperative Agreements
Supplementing Title 7 of the Code of Federal Regulations

1. APPLICABLE REGULATIONS

The Recipient agrees to comply with the following Regulations as applicable:

- a. 7 CFR 3015.205, General Provisions for Grants and Cooperative Agreements with Institutions of Higher Education, Other Non-profit Organizations, and Hospitals.
- b. 7 CFR 3016, Uniform Administrative Requirements for Grants and Cooperative Agreements to State and Local Governments.
- c. 7 CFR 3017, Government Wide Debarment and Suspension (Non procurement) and Government wide Requirements for Drug-Free Workplace (Grants).
- d. 7 CFR 3018, New Restrictions on Lobbying
- e. 7 CFR 3019, Uniform administrative requirements for Grants and Agreements with Institutions of Higher Education, Hospitals, and Other Non-Profit Organizations.

2. ASSURANCES AND COMPLIANCES

Recombinant DNA Research.

The Recipient will assume primary responsibility for implementing proper conduct of recombinant DNA research and it will comply with the National Institutes of Health Guidelines for Recombinant DNA Research, as revised.

If the Recipient wishes to send or receive registered recombinant DNA material which is subject to quarantine laws, permits to transfer this material into the U.S. or across state lines may be obtained by contacting:

USDA/APHIS/PPQ, Scientific Services-Biotechnology Permits, 4700 River Road, Unit 133, Riverdale, Maryland 20737.

In the event that the Recipient has not established the necessary biosafety committee, a request for guidance or assistance may be made to the USDA Recombinant DNA Research Officer.

Grant recipients are required to complete Form ARS-411, Research Assurance Statement when it is anticipated that the research project will involve recombinant DNA research.

3. ACKNOWLEDGMENT OF SUPPORT AND DISCLAIMER

- a. *Publications.* Recipient shall acknowledge awarding agency support, whether cash or in-kind, in any publications written or published with Federal support and, if feasible, on any publication reporting the results of, or describing, a Federally supported activity.
- b. *Audiovisuals.* Recipient shall acknowledge awarding agency support in any audiovisual produced with Federal support that has a direct production cost to the recipient of over \$5,000. Unless the terms of the Federal award provide otherwise, this requirement does not apply to:
 - (1) Audiovisuals produced under mandatory or formula grants or under
 - (2) Audiovisuals produced as research instruments or for documenting experimentation or findings and not intended for presentation or distribution to the general public.
- c. *Waivers.* Awarding agencies may waive any requirements of 7 CFR 3020.13. Awarding agencies may establish such requirements and procedures for the waiver process as they deem necessary.

4. PAYMENT METHODS

The recipient agrees to accept payment by either HHS/Payment Management System, Treasury check or Electronic Funds Transfer (EFT).

5. PERFORMANCE REPORTS

- a. *Financial Reports.* See Form REE-451 for financial reporting frequency applicable to this Agreement.
- b. *Performance Reports.* See Form REE-451 for performance reporting frequency applicable to this Agreement.
- c. *Invention Disclosure and Utilization Reports.*

Disclosure and Utilization Reporting - The Recipient shall report Invention Disclosures and Utilization information electronically via iEdison Web Interface at: <http://www.iedison.gov/>. (Negative reporting not required)

If Interagency Edison is unavailable, Invention Disclosure and Utilization Reporting may be submitted by U.S. Mail directly to:

*DEITR, National Institutes of Health
6701 Rockledge Drive, Room 3175, MSC 7750
Bethesda, Maryland 20892-7750*